A Lahoz and A Hall srGAP3, a member of the Slit-Robo sub-family of Rho GTPase-activating proteins (Rho GAPs), controls actin and microtubule dynamics through negative regulation of Rac. Here, we describe a potential role for srGAP3 as a tumor suppressor in mammary epithelial cells. We show that RNAi-mediated depletion of srGAP3 promotes Rac dependent, anchorage-independent growth of partially transformed human mammary epithelial cells (HMECs). Furthermore, srGAP3 expression is absent, or significantly reduced in 7/10 breast cancer cell lines compared with normal HMECs. Re-expression of srGAP3 in a subset of these cell lines inhibits both anchorage-independent growth and cell invasion in a GAP-dependent manner, and this is accompanied by an increase in phosphorylation of the ezrin/radixin/moesin (ERM) family proteins and myosin light chain 2 (MLC2). Inhibition of the Rho regulated kinase, ROCK, reduces ERM and MLC2 phosphorylation and restores invasion. We conclude that srGAP3 has tumor suppressor-like activity in HMECs, likely through its activity as a negative regulator of Rac1.
INTRODUCTION
Rho family small GTPases regulate a wide range of cellular processes involved in transformation, including adhesion, polarity, migration, proliferation and cell survival. Unlike their close relative Ras, mutations in Rho GTPases are not found in tumors, though there have been numerous reports of aberrant expression of Rho, Rac, Cdc42, Rnd3/RhoE and Wrch2/rhoV in a variety of human cancers. 1, 2 Further analysis has suggested that signaling pathways controlled by Rho family members can contribute to tumorigenesis at many stages, from initiation through to metastasis. 1 Like other members of the Ras superfamily, Rho GTPases act as molecular switches cycling between an active GTP-bound state and an inactive GDP-bound state. Cycle activation is promoted by guanine nucleotide exchange factors (Rho GEFs) that catalyze exchange of GDP with GTP, while inactivation is mediated by GTPase-activating proteins (Rho GAPs) that stimulate intrinsic GTPase activity. 3 Mutations or altered expression of these regulatory proteins might be expected to promote dysregulated downstream signaling. Many members of the large GEF family, including b-Pix, Vav, Dbl and Lbc, have been shown experimentally to act as dominant oncogenes after deletion of their (usually N-terminal) autoinhibitory domains, though there are only sporadic reports of such deletions in human cancers. 1, 4 In contrast, Rho family GAPs, such as DLC1, p190RhoGAP and b-chimaerin have been reported to act as tumor suppressors in human tumors. 5, 6 The Slit-Robo GTPase-activating proteins (srGAPs) are a subfamily of Rho GAPs that act downstream of the Robo receptor. In mammals, the srGAP family consists of four members, srGAP1, 2, and 3, and a more distantly related member, ARHGAP4. They mediate protein-protein interactions and signal transduction through a Rho GAP domain, an SH3 domain, and a Fes CIP4 homology domain; notably, the SH3 domain of srGAP3 interacts with the cytoplasmic domain of Robo. 7, 8 Tissue culture studies indicate that srGAP1 transduces the Slit repulsion signal affecting neuronal migration through downregulation of Cdc42 and activation of RhoA, 8 while srGAP2 is involved in axon regeneration and neuronal migration. 9 ,10 srGAP3 (also named MEGAP and WRP) has been implicated in X-linked mental retardation. 11 In NIH3T3 cells, srGAP3 localizes to the plasma membrane through its F-Bar domain and to focal adhesions through its SH3 domain. 12 Its expression downregulates Rac activity, and thereby impairs actin and microtubule dynamics, and the formation of protrusions and focal adhesions. 11, 13 Furthermore, srGAP3 binds to the Arp2/3-activating protein Wave-1 and the Wave-1/srGAP3 complex is important for the development of dendritic spines in primary hippocampal neurons. [14] [15] [16] In the present study, we show that srGAP3 depletion cooperates with the oncogenes LT and c-myc to induce transformation in human mammary epithelial cells (HMECs). Moreover, a significant number of breast cancer cell lines have low levels of both srGAP3 mRNA and protein. Restored expression of srGAP3 reduces soft agar colony formation, invasion and 3D growth of breast cancer cells, in a GTPase-dependent manner. These results suggest a potential role for srGAP3 as a tumor suppressor in human breast cancer.
RESULTS AND DISCUSSION
srGAP3 depletion induces anchorage-independent growth in early passage, immortalized HMECs Cellular transformation typically requires multiple genetic alterations. HMECs have been reported to undergo partial transformation after expression of hTERT, large T antigen and c-myc. However, additional changes, in particular hyperactivation of the PI 3-kinase pathway (through constitutively activated PI3KCA, or downregulation of PTEN) are required to promote anchorage-independent growth. 17, 18 Further analysis revealed that at least one function of PI 3-kinase pathway activation in this context was activation of the Rac GTPase. 18 To explore the possibility that members of the Rho GAP family might act as tumor suppressors in these partially transformed mammary epithelial cells (HMECs), we transfected early passage HMEC/ hTERT/LT/c-myc cells with small interference RNA SmartPool duplexes (Dharmacon, Lafayette, CO, USA) targeting the 66 known human GAPs (Supplementary Table S1 ). The ability of transfected cells to grow in an anchorage-independent manner was then assessed, using a small interference RNA against PTEN as a positive control (Figures 1a and b) . Depletion of srGAP3, consistently induced anchorage-independent growth as efficiently as PTEN loss (Figures 1a and b) . Further analysis revealed that each of the four individual duplexes comprising the SmartPool reduced srGAP3 protein expression and significantly increased colony formation (Figure 1c ), indicating that this is a specific effect of srGAP3 depletion. We conclude that srGAP3 downregulation induces anchorage-independent growth in HMECs expressing the oncogenes LT and c-myc. Several other potential candidates were obtained in the screen, but as these have not been validated we cannot confirm whether other GAPs also function as tumor suppressors in HMECs.
There have been conflicting reports as to the GTPase specificity of srGAP family proteins, though it appears that Rac is the likely target. 11, 12, 15, 19 We were unable to detect any significant changes in the total cellular GTP-bound Rac or Cdc42, using GST-PAK-CRIB pull-down experiments after depletion of srGAP3 in HMECs (data not shown). It was reported that both AKT phosphorylation and Rac activation are required to induce transformation in late passage of HMEC/hTERT/LT cells. 18 However, we could not detect any significant increase in AKT phosphorylation after srGAP3 depletion, although this was clearly observed in the PTEN depletion experiments (Supplementary Figure S1a) . Furthermore, expression of constitutively activated Rac-induced cell death in anchorage-independent growth experiments, as previously described (Supplementary Figure S1b) . 18 As an alternative to examine srGAP3 specificity, we depleted Rac1 together with srGAP3 in the HMEC/hTERT/LT/c-myc cell line. As shown in Figure 1d , Rac1 depletion suppressed the anchorage-independent growth caused by srGAP3 downregulation. This result suggests that srGAP3 likely controls the growth of mammary epithelial cells through regulation of Rac1, although it is possible that anchorageindependent growth of these cells is Rac1-dependent for other reasons.
srGAP3 expression is reduced in breast cancer cell lines in part by epigenetic regulation To investigate its potential wider role in breast cancer, srGAP3 protein levels were analyzed on western blots in a panel of human breast cancer cell lines, using immortalized HMECs and MCF10A cells as 'normal' controls. As shown in Figure 2a . 18 The cells were transiently transfected with 60 nM of PTEN small interference RNA (siRNA; L-003023, Dharmacon) or srGAP3 siRNA (M-014175-00, Dharmacon SmartPool) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Four days after transfection, 1 Â 10 4 cells were seeded in 0.4% agar in a 24-well plate (protocol adapted from Zhao et al.
18
). After 3 weeks, colonies were stained with 0.5 mg/ml of MTT (3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide, Sigma, St Louis, MO, USA) and colonies 450 mm in diameter were scored using a GelCount colony counter (Oxford Optronix Ltd, Oxford, UK). A nontargeting siRNA (D-001210-02, Dharmacon) was used as a control for non-sequence-specific effects. Results shown are the mean of eight independent experiments ±s.e.m. ***P40.001. Cells were lysed 4 days after transfection in RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) plus 100 mM PMSF Role of srGAP3 as a tumor suppressor A Lahoz and A Hall
To determine whether srGAP3 downregulation occurs pre-or post-translationally, we analyzed mRNA levels by quantitative-PCR (Q-PCR) in the cell lines expressing low levels of the protein. As shown in Figure 2b , srGAP3 mRNA levels were significantly downregulated in each case, compared with the HMEC control. Importantly, we also found two data sets in Oncomine (Compendia Bioscience, Ann Arbor, MI, USA) demonstrating srGAP3 mRNA downregulation in ductal breast carcinoma (Figure 1c) , consistent with the loss of srGAP3 in a significant number of human breast cancers. 20, 21 To analyze whether srGAP3 is differentially expressed in certain types of breast tumor, three data sets were analyzed from ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) (Accession Numbers: E-GEOD-3744, E-GEOD-36771 and E-MTAB-1088). No significant differences in srGAP3 expression levels were found between (i) basal-like and non-basal like tumors (E-GEOD-3744), (ii) ER þ and ER À /PR À tumors (E-GEOD-36771) and (iii) ER þ and ER À /PR À /Her2 À tumors (E-MTAB-1088) (data not shown). Each data set was normalized using Gene Chip Robust Multiarray Averaging (GR-RMA), and fold change was calculated using Linear Models for Microarray Data (Limma). Both algorithms were run using R scripts.
The srGAP3 gene is localized on chromosome 3p25, a region whose deletion occurs in 3p-syndrome, and is associated with various developmental defects. 11, 22 Based on these results, we 15 mM HEPES and 10% serum; MCF10A in DMEM F12 supplemented with 20 ng/ml EGF, 0.5 mg/ml hydrocortizone, 100 ng/ml cholera toxin, 10 mg/ml insulin and 5% of horse serum. All cell lines were cultured with antibiotics at 37 1C and 5% CO 2 except MDA-MB-231 and MDA-MB-468, which were incubated without CO 2 . (b) srGAP3 mRNA expression was analyzed by Q-PCR. Total cellular RNA was isolated from cells lines with the RNAeasy Mini kit (74104 Qiagen, Valencia, CA, USA). Reverse transcription-PCR (RT-PCR) was performed using SuperScript One-Step RT-PCR kit (Invitrogen) using 200 ng of total RNA for each reaction. Quantitative-PCR was performed using taqman reagents on the 7500 real-time PCR system (Applied Biosystem, Carlsbad, CA, USA). mRNA expression levels of srGAP3 (Hs00322672_m1, Applied Biosystem) were normalized to GAPDH mRNA levels (Hs99999905_m1, Applied Biosystem). Data are represented as fold inductions relative to HMECs. **Po0.01; ***Po0.001. (c) Oncomine microarray data analysis of srGAP3 expression in human breast cancer vs normal breast tissue is shown. The Student's t-test was conducted using the Oncomine software (http://www.oncomine.org). The boxes represent the 25th through 75th percentiles; the horizontal lines represent the medians; the points represent the end of the ranges. In the left panel, 18 samples were analyzed and compared with 6 normal samples. 20 In the right histogram a total of 32 invasive ductal breast carcinomas samples were compared with 3 normal samples. 21 (d) srGAP3 expression levels were measured after inhibition of DNA methylation using 5-azacytidine, (5-AzaC, Sigma A2385) or histone deacetylation using trichostatin A, (TSA, Sigma T8552) in MCF7, BT549 and BT474 breast cancer cell lines. 1 Â 10 5 cells were plated the day before treatment in a six-well plate and 5 mM or 10 mM of 5-AzaC was added for 96 h and 0.5 mM of TSA was added for 20-24 h. Protein lysates and RNA levels were analyzed after treatment. *Po0.05; **Po0.01; ***Po0.001.
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A Lahoz and A Hall reasoned that deletion or translocation of the srGAP3 locus might underlie the downregulation seen in breast cancer. However, FISH results revealed no deletions or translocations of the srGAP3 locus in the breast cancer cell lines analyzed (Supplementary Table S2 ). We next considered the possibility that srGAP3 expression levels may be affected by epigenetic regulation. MDA-MB-231, Hs578t, SKBR7, BT474, BT549, MCF7 and SKBR3 cell lines were treated with optimized concentrations of the inhibitors 5-azacytidine (5-AzaC, an inhibitor of methyltransferases) and trichostatin A (TSA, an inhibitor of histone deacetylases). Both compounds have been shown to relax chromatin and allow transcription of genes affected by epigenetic regulation. 23 5-AzaC had no significant effect, but TSA increased the levels of both srGAP3 mRNA and protein in a subset of lines, namely MCF7, BT549 and BT474 (Figure 2d ). Based on these results we conclude that srGAP3 expression can be transcriptionally regulated, in part through histone deacetylation. Interestingly, endogenous srGAP3 is upregulated in the neuroblastoma cell line, Neuro 2A after differentiation by valproic acid, an inhibitor of histone deacetylases. 19 Moreover, a novel histone deacetylase inhibitor (OSU-HDAC-44) induces the expression of srGAP1 and suppresses tumor growth in non-small-cell lung cancer models. 24 Alongside our 5 cells resuspended in 500 ml of serum-free media were plated into the upper chamber of a 8-mm-pore transwell filter (BD biosciences 354480) suspended in a 24-well plate. The medium below the transwell was supplemented with 10% FBS. Cells were allowed to invade for 20-22 h at 37 1C. Cells in the upper part of the chamber were scraped away with a cotton swab, and the cells on the bottom of the chamber were washed with PBS, fixed with methanol for 10 min at À 20 1C and stained with Hoechst. Filter images were acquired with a Â 5 objective using a mosaic function and acquiring 7 Â 7 images in an Axiovert 200 M microscope. The number of invaded cells was assessed by nuclei quantification using metamorph software. Every experiment was repeated three times in quadruplicate. Measurements shown represent the mean ± s.e.m. *Po0.05. current findings, these data suggest that the expression of srGAP family members can be regulated by histone acetylation in different contexts.
Finally, neither DNA methylation, nor histone deacetylase inhibitors affected the expression levels of srGAP3 in SKBR3, SKBR7, MDA-MB-231 or Hs578t cells. In SKBR3 and SKBR7 cells, TSA treatment induced a significant increase in srGAP3 mRNA, but did not change srGAP3 protein expression (Supplementary Figure S2) ; in MDA-MB-231 and Hs578t, both mRNA and protein levels are unaffected, suggesting additional mechanisms of transcriptional control.
srGAP3 overexpression reduces transformed growth in breast cancer cell lines Based on the data presented so far, we reasoned that srGAP3 might have tumor suppressor-like activity in mammary epithelial cells. To examine this further, full length srGAP3 or a mutant version lacking GAP activity (srGAP3DGAP) were re-expressed in the breast cancer cell lines having low endogenous levels. 15 Figure S3a) . Strikingly, re-expression of srGAP3 in MDA-MB-231 or MCF7 induced a significant decrease in soft agar colony formation compared with control cells expressing only an empty vector (Figure 3a, Supplementary Figure S3b) . Importantly, in both cases, srGAP3DGAP did not affect colony formation, indicating that suppression is mediated through downregulation of a Rho family GTPase. These data are consistent with a tumor suppressive role for srGAP3 in these cells.
Expression constructs were introduced into cells by transient transfection or retroviral infection (Supplementary
srGAP3 expression inhibits breast cancer cell invasion Cancer progression typically involves an increase in the invasive potential of cells. As srGAP proteins and Rho GTPases have been implicated in cytoskeletal dynamics, focal adhesion regulation and cell migration, srGAP3 might regulate breast cancer cell invasion, as well as transformed growth. To test this, we used both 3D and 2D invasion assays to examine a potential role of srGAP3 in these aspects of cancer cell behavior. Several studies have made use of a 3D Matrigel colony formation assay in which colony morphology correlates with invasive behavior in a number of breast cancer cell lines. 25 Non malignant cells, such as MCF10A or HMEC, form spheroid shaped colonies when suspended in 3D matrigel cultures, whereas highly metastatic breast cancer cells, such as MDA-MB-231, BT549 and Hs578t, grow as stellate forms, and exhibit projections that bridge multiple cell colonies and organize into a continuous network. 25, 26 Cell lines showing a stellate phenotype also show invasive activity in conventional, 2D transwell invasion assays. 27, 28 Consistent with previous work, MDA-MB-231 and BT549 cells grown in 3D Matrigel cultures, form stellate structures typical of malignant cells, as observed by actin staining (Figures 3b and c,  Supplementary Figures S4 and S5 ) or phase microscopy ( Supplementary Figures S4 and S5 ). In contrast, cells engineered to re-express srGAP3 show a significant reduction in the number of stellate forms, as well as in the length of the projections that do form (Figures 3b and c, Supplementary Figures S4 and S5) . Interestingly, srGAP3DGAP does not reduce the ability of these two breast cancer cell lines to form stellate colonies in 3D ( Figures  3b and c, Supplementary Figures S4 and S5 ). These data demonstrate that srGAP3 influences the invasive potential of breast cancer cells in a GAP-dependent manner. In agreement with this, expression of wild-type srGAP3, but not srGAP3DGAP, significantly inhibits invasion of MDA-MB-231 in a 2D matrigel, transwell chamber assay (Figure 3d ). Together, these results suggest that expression of srGAP3 inhibits the invasive capacity of breast cancer cells in a GTPase-dependent manner.
srGAP3 expression induces loss of invasive behavior through increased ROCK/actomyosin activity In the course of these experiments, we observed that expression of srGAP3 in MDA-MB-231 caused increased cell rounding. Visualization of actin, with rhodamine-phalloidin, revealed active blebbing at the cell surface indicating an increase in actin contractility (Figure 4a ). Phosphorylation of ezrin/radixin/moesin (ERM) family proteins and myosin light chain 2 (MLC2) has been described to be important for the ameboid movement of melanoma cells, which is driven by actomyosin contractility resulting in membrane blebbing. [29] [30] [31] As shown in Figure 4b , the ectopic expression of srGAP3 in MDA-MB-231 led to elevated levels of phospho-ERM and phospho-MLC2, while total protein levels were unchanged. These effects are GTPase dependent, as srGAP3DGAP expression did not increase phosphorylation of ERM and had only a small effect on MLC2 phosphorylation.
The Rho regulated kinase ROCK phosphorylates a range of cytoskeletal proteins, including ERM and MLC2. 32, 33 To determine whether the effect of srGAP3 expression on the invasive behavior of MDA-MB-231 is related to an increase in ROCK activity, MDA-MB-231 cells expressing srGAP3 were treated with the ROCK inhibitor, Y-27632. We observed that the phosphorylation levels of ERM and MLC2 were dramatically reduced upon Y-27632 treatment (Figure 4c ) and that this rescued the ability of srGAP3-expressing MDA-MB-231 cells to form invasive, stellate colonies in 3D Matrigel assays (Figure 4d , Supplementary Movies S1 and S2). Together, these data suggest that srGAP3 expression leads to Rho and ROCK activation, likely through inactivation of Rac, to drive actomyosin contractility and inhibit cancer cell invasion.
In summary, we provide evidence that srGAP3 has tumor suppressor-like activity in HMECs. Depletion of srGAP3 in partially transformed HMECs promotes Rac1-dependent, anchorage-independent growth and the expression of srGAP3 is downregulated in 7 (of 10) human breast cancer cell lines examined. Ectopic re-expression of srGAP3 in a subset of these lines inhibits anchorage-independent growth and invasion in a GAP-dependent manner. Interestingly, others have reported upregulation of the Rac exchange factor pREX-1 in human breast cancers. 34 The results we describe here add further support for an important role for Rac in this disease. Finally, the inhibition of MDA-MB-231 invasion activity after srGAP3 expression correlates with an increase in the activity of Rho/ROCK/actomyosin signaling. As, Rac and Rho have been shown to have antagonistic activities in many cellular contexts, we conclude that inhibition of Rac by srGAP3 in mammary epithelial cells likely leads to upregulation of Rho activity. 31, 35, 36 The mechanisms underlying this cross-talk are currently being addressed.
